by Madaline Spencer | Oct 31, 2025
Philip J. Ferrone, MD, Vitreoretinal Consultants of New York, discusses results from the TEASE-2 clinical trial of gildeuretinol in patients with Stargardt disease. Stargardt disease is a genetic eye disorder that causes progressive vision loss. It...
by Madaline Spencer | Oct 30, 2025
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) for the treatment of relapsed/refractory acute myeloid leukemia (AML). The indication is for adult and pediatric patients one year of age and older with a susceptible nucleophosmin 1 (NPM1)...
by Madaline Spencer | Oct 28, 2025
Wildon Farwell, MD, Chief Medical Officer at Satellos, discusses the safety and efficacy of SAT-3247 to treat adults with Duchenne muscular dystrophy (DMD). DMD is a genetic neuromuscular disorder characterized by progressive muscle wasting. DMD occurs...
by Madaline Spencer | Oct 27, 2025
The U.S. Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (MM). The indication is for those who have...
by Madaline Spencer | Oct 24, 2025
Lawrence Lustig, MD, Professor at Columbia University Medical Center, discusses early results from the CHORD clinical trial testing gene therapy to treat otoferlin-related hearing loss. Otoferlin (OTOF)-related hearing loss is a rare genetic auditory...
